‍Tours, France, June 11,2025 9:00AM CET – MAbSilico, a pioneering French TechBio company specializing in antibody technology, today announced an exclusive partnership with YntoAb Co., Ltd., a leading Korean Contract Research Organization (CRO) specialized in antibody discovery. This collaboration marks a significant step in bringing MAbSilico’s cutting-edge AI-based antibody analysis services to the South Korean biopharmaceutical and research sectors.

This strategic partnership is poised to significantly increase MAbSilico’s business development by extending its commercial growth into South Korea. This expansion is a key component of MAbSilico's participation in the recent France 2030Export program by Business France, which actively supports French companies in their international development.

MAbSilico, trusted by global pharmaceutical giants, leverages a unique fusion of Bioinformatics, Structural Biology, and Artificial Intelligence to accurately predict complex antibody-antigen interactions within an unprecedented timeframe. The company's validated technology, recognized through scientific publications and international patents, is already empowering leading biotech and pharmaceutical companies across Europe and the United States.

Through this exclusive agreement, YntoAb will offer a suite of powerful AI-driven antibody analysis services in Korea, including:

·      Epitope Mapping: Precise, structure-based prediction of antibody-antigen binding sites for rapid and accurate antibody characterization and optimization.

·      Antibody Specificity Prediction: AI algorithms that proactively identify potential off-target binding, minimizing the risk of development failure.

·      Developability Assessment: Data-driven insights to evaluate commercialization potential through comprehensive cross-reactivity and developability analyses.

·      Sequence-to-Structure Modeling: High-resolution 3D structure prediction from antibody sequences, enabling advanced structural analysis, epitope-driven antibody design, and customized antibody engineering.

These services are particularly valuable for:

·      Researchers seeking rapid characterization of novel antibody candidates.

·      Antibody development teams focused on designing epitope-based functional antibodies.

·      Biotech companies aiming to mitigate early-stage development risks.

·      Professionals looking to obtain crucial binding prediction data prior to experimental validation.

"We are incredibly enthusiastic about this partnership with YntoAb, a highly respected CRO with deep expertise in antibody discovery within the dynamic South Korean market," says Zakaria Omahdi, Scientific Business Developer at MAbSilico." This collaboration represents a significant step in our global expansion strategy, bringing our cutting-edge AI-powered solutions to a new and important region. We are confident that by combining our innovative technology with YntoAb’s strong presence, we will significantly accelerate antibody research and development in South Korea and contribute to the advancement of novel therapeutics."

"Partnering with MAbSilico allows us to introduce Korea's first AI-based antibody analysis services, offering a transformative advantage to our clients," says Sungyoung Lee, CEO of YNTOAB Co., Ltd.. "MAbSilico's world-leading AI technology will empower Korean researchers and biotech companies to accelerate their antibody discovery and development pipelines, ultimately leading to more efficient and successful outcomes and fostering innovation in our biopharmaceutical sector."

The AI-based antibody analysis services are now officially available through YntoAb. Researchers and companies interested in revolutionizing their antibody research and development are encouraged to contact YntoAb for more information and to explore the possibilities of digital biology.

‍